chore boy
Established Member
- Reaction score
- 1
Seems Pueraria mirifica may be a PTH inhibitor or at least decrease its levels. If we could get PM in a nano/lipo formulation, it might be worth trying out. Does anyone know of any other natural PTH inhibitors?
Abstract: To determine the effect of Pueraria mirifica (PM) on serum parathyroid hormone (PTH) and calcium levels on aged menopausal monkeys (Macaca fascicularis), subjects were treated with 10, 100, or 1,000 mg/day of PM. Blood samples were collected every 5 days for 30, 90, and 60 days during pre-treatment, treatment, and post-treatment periods, respectively. Sera were assayed for PTH, estradiol, and calcium levels. PM-1,000 had the strongest effect on the decrease in PTH (0.001<P=0.05) and calcium levels (0.001<P=0.03) during the treatment period. PTH levels remained low for the first 15 days of the post-treatment period (0.01=P=0.05). PM-10 induced a significant decrease in PTH level on day 80 (P=0.02) during the treatment period and a significant decrease in calcium level on day 75 (P<0.01). There were no changes in serum PTH and calcium levels throughout the study period in the PM-100 group. Estradiol levels decreased significantly during the treatment period in all treatment groups. The results suggest that long-term treatment with 1,000 mg/day of PM decreases serum PTH and calcium levels in aged menopausal monkeys, indicating that PM ameliorates bone loss caused by oestrogen deficiency.
http://www.cababstractsplus.org/abstrac ... 0053044732
One of the biggest hurdles in developing peptides for the treatment of hair growth disorders is that there has been no effective method of delivering them topically. Murine hair growth can be stimulated with ip injections of the PTH/PTHrP receptor antagonist, PTH (7–34). We sought to determine whether we could deliver PTH (7–34) topically and achieve stimulation of hair growth. We prepared a topical cream by mixing PTH (7–34) into a liposome vehicle (Novasome A). We applied the cream daily to the backs of 5-wk-old female SKH-1 hairless mice for 1 wk. After the 1 wk of treatment, there was marked stimulation of hair growth in the SKH-1 hairless mice. Relative to controls, mice treated with PTH (7–34) had 216% longer hairs (P < 0.001), 40% more visible hairs (P < 0.001), and 43% more hair follicles stained with 5-bromo-2'-deoxyuridine (P < 0.01). A unique aspect of skin is the possibility to directly target it via topical treatment. Our study is the first to report the hair-stimulating effect of a PTH/PTHrP receptor antagonist topically applied to skin in vivo. Thus, we introduce a novel paradigm to develop topical PTH analogs for treating disorders of hair growth.
http://endo.endojournals.org/cgi/conten ... 148/3/1167
The biologic action of parathyroid hormone (PTH)-related peptide (PTHrP) in normal skin was investigated in cultured human keratinocytes and in SKH-1 hairless mice. The results indicate that the PTHrP agonists human PTHrP-(1-34) and PTH(1-34) are potent inhibitors of epidermal cell proliferation. [Nle8,18,Tyr34]bovine PTH-(7-34)-amide, an antagonist of the PTH/PTHrP receptor, blocked the inhibitory effect of PTH-(1-34) in cultured keratinocytes. In the SKH-1 mice, PTH-(7-34) caused a 244% increase of [3H]thymidine incorporation into isolated epidermal DNA and 246% and 180% increases in the number and length of hair shafts, respectively. Thus, PTH and PTHrP may play an important role in the normal physiology of skin, and their agonists and antagonists have potentially wide therapeutic applications in the treatment of hyperproliferative skin disorders and aging skin and could also be effective in stimulating and maintaining hair growth.
http://www.pubmedcentral.nih.gov/articl ... rtid=44535
Abstract: To determine the effect of Pueraria mirifica (PM) on serum parathyroid hormone (PTH) and calcium levels on aged menopausal monkeys (Macaca fascicularis), subjects were treated with 10, 100, or 1,000 mg/day of PM. Blood samples were collected every 5 days for 30, 90, and 60 days during pre-treatment, treatment, and post-treatment periods, respectively. Sera were assayed for PTH, estradiol, and calcium levels. PM-1,000 had the strongest effect on the decrease in PTH (0.001<P=0.05) and calcium levels (0.001<P=0.03) during the treatment period. PTH levels remained low for the first 15 days of the post-treatment period (0.01=P=0.05). PM-10 induced a significant decrease in PTH level on day 80 (P=0.02) during the treatment period and a significant decrease in calcium level on day 75 (P<0.01). There were no changes in serum PTH and calcium levels throughout the study period in the PM-100 group. Estradiol levels decreased significantly during the treatment period in all treatment groups. The results suggest that long-term treatment with 1,000 mg/day of PM decreases serum PTH and calcium levels in aged menopausal monkeys, indicating that PM ameliorates bone loss caused by oestrogen deficiency.
http://www.cababstractsplus.org/abstrac ... 0053044732
One of the biggest hurdles in developing peptides for the treatment of hair growth disorders is that there has been no effective method of delivering them topically. Murine hair growth can be stimulated with ip injections of the PTH/PTHrP receptor antagonist, PTH (7–34). We sought to determine whether we could deliver PTH (7–34) topically and achieve stimulation of hair growth. We prepared a topical cream by mixing PTH (7–34) into a liposome vehicle (Novasome A). We applied the cream daily to the backs of 5-wk-old female SKH-1 hairless mice for 1 wk. After the 1 wk of treatment, there was marked stimulation of hair growth in the SKH-1 hairless mice. Relative to controls, mice treated with PTH (7–34) had 216% longer hairs (P < 0.001), 40% more visible hairs (P < 0.001), and 43% more hair follicles stained with 5-bromo-2'-deoxyuridine (P < 0.01). A unique aspect of skin is the possibility to directly target it via topical treatment. Our study is the first to report the hair-stimulating effect of a PTH/PTHrP receptor antagonist topically applied to skin in vivo. Thus, we introduce a novel paradigm to develop topical PTH analogs for treating disorders of hair growth.
http://endo.endojournals.org/cgi/conten ... 148/3/1167
The biologic action of parathyroid hormone (PTH)-related peptide (PTHrP) in normal skin was investigated in cultured human keratinocytes and in SKH-1 hairless mice. The results indicate that the PTHrP agonists human PTHrP-(1-34) and PTH(1-34) are potent inhibitors of epidermal cell proliferation. [Nle8,18,Tyr34]bovine PTH-(7-34)-amide, an antagonist of the PTH/PTHrP receptor, blocked the inhibitory effect of PTH-(1-34) in cultured keratinocytes. In the SKH-1 mice, PTH-(7-34) caused a 244% increase of [3H]thymidine incorporation into isolated epidermal DNA and 246% and 180% increases in the number and length of hair shafts, respectively. Thus, PTH and PTHrP may play an important role in the normal physiology of skin, and their agonists and antagonists have potentially wide therapeutic applications in the treatment of hyperproliferative skin disorders and aging skin and could also be effective in stimulating and maintaining hair growth.
http://www.pubmedcentral.nih.gov/articl ... rtid=44535
